Image Place holder

Bill Dalton, PhD, MD

Specialty: Medical Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT

Call 1-888-MOFFITT


Dr. William Dalton is CEO of M2Gen, a Moffitt Cancer Center biotechnology company.  Additionally, he is founding director of Moffitt’s Personalized Medicine Institute, established in 2012 to focus on Moffitt’s brand of personalized medicine, Total Cancer Care®. Dr. Dalton served as president and CEO of Moffitt from 2002 to 2012 and was instrumental in helping the Cancer Center achieve tremendous growth and innovation.  He facilitated the launch of M2Gen and the development of Moffitt Total Cancer Care®. Dr. Dalton received his Ph.D. and medical degree from Indiana University School where he completed an internship in medicine. He then completed a residency in medicine and fellowships in oncology and clinical pharmacology at the University of Arizona in Tucson. He joined the University of Arizona medical school faculty, where he became professor and dean of the College of Medicine. He also directed the Bone Marrow Transplant Program at the Arizona Cancer Center. Dr. Dalton joined Moffitt in 1996 and served as associate center director for clinical investigations and deputy director of the cancer center.  He also founded and chaired the Department of Interdisciplinary Oncology at the University of South Florida where he is a professor of oncology.  Dr. Dalton left Moffitt briefly in 2001 to serve as dean of the College of Medicine at the University of Arizona, returning in 2002 as the cancer center’s president, CEO and center director. A medical oncologist, Dr. Dalton has been a principal investigator or co-investigator for numerous research studies in his specialty of malignant hematology.  Over his career, Dr. Dalton has published extensively, served on numerous editorial advisory boards for professional publications, participated extensively on committees for National Institute of Health/National Cancer Institute, American Association of Cancer Research, American Society of Hematology and the American Society of Clinical Oncology.  He has also served on many university-based scientific advisory boards.  

Education & Training

Board Certification:

  • Medical Oncology


  • University of Arizona - Oncology
  • University of Arizona - Clinical Pharmacology


  • University of Arizona - Medicine

Medical School:

  • Indiana University - MD
Start Year: 2013 End Year: Fellow, Sponsor: National Academy of Inventors
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Scott JG, Sedor G, Scarborough JA, Kattan MW, Peacock J, Grass GD, Mellon EA, Thapa R, Schell M, Waller A, Poppen S, Andl G, Teer J, Eschrich SA, Dilling TJ, Dalton WS, Harrison LB, Fox T, Torres-Roca JF. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. J Thorac Oncol. 2021 Mar.16(3):428-438. Pubmedid: 33301984.
  • Seligson ND, Warner JL, Dalton WS, Martin D, Miller RS, Patt D, Kehl KL, Palchuk MB, Alterovitz G, Wiley LK, Huang M, Shen F, Wang Y, Nguyen KA, Wong AF, Meric-Bernstam F, Bernstam EV, Chen JL. Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity. J Am Med Inform Assoc. 2020 Nov.27(11):1808-1812. Pubmedid: 32885823. Pmcid: PMC7671612.
  • Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Dan Rozelle, Danziger SA, Ratushny A, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 Jul.34(7):1866-1874. Pubmedid: 32060406. Pmcid: PMC7326699.
  • Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 2019 May.35(5):752-766.e9. Pubmedid: 31085176. Pmcid: PMC6945775.
  • Stanková K, Brown JS, Dalton WS, Gatenby RA. Optimizing Cancer Treatment Using Game Theory: A Review. JAMA Oncol. 2019 Jan.5(1):96-103. Pubmedid: 30098166. Pmcid: PMC6947530.
  • Dalton WS, Sullivan D, Ecsedy J, Caligiuri MA. Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clin Pharmacol Ther. 2018 Jul.104(1):23-26. Pubmedid: 29570791. Pmcid: PMC6032821.
  • Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham L, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018 Dec.128(12):5517-5530. Pubmedid: 30260324. Pmcid: PMC6264635.
  • Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017 Mar.58(3):560-568. Pubmedid: 27424609. Pmcid: PMC7771364.
  • Li B, Eschrich SA, Berglund A, Mitchell M, Fenstermacher D, Danaee H, Dai H, Sullivan D, Trepicchio WL, Dalton WS. Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility. JMIR Res Protoc. 2017 Mar.6(3):e45. Pubmedid: 28320689. Pmcid: PMC5379017.
  • Silva AS, Silva MC, Sudalagunta P, Distler AI, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt CL, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby RA, Gillies RJ, Sontag E, Meads MB, Shain K. An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res. 2017 Jun.77(12):3336-3351. Pubmedid: 28400475. Pmcid: PMC7819642.
  • Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017 Feb.18(2):202-211. Pubmedid: 27993569. Pmcid: PMC7771305.
  • Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017 Apr.8:14920. Pubmedid: 28416797. Pmcid: PMC5399304.
  • Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med. 2016 Jul.5(7):1694-1701. Pubmedid: 27098006. Pmcid: PMC4944897.
  • Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016 Aug.9(1):73. Pubmedid: 27557643. Pmcid: PMC4997728.
  • Shain KH, Dalton WS, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene. 2015 Sep.34(36):4673-4682. Pubmedid: 25639873. Pmcid: PMC4688902.
  • Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Eur J Haematol. 2015 Nov.95(5):426-435. Pubmedid: 25600676. Pmcid: PMC4508238.
  • Coppola D, Balducci L, Chen DT, Loboda A, Nebozhyn M, Staller A, Fulp WJ, Dalton W, Yeatman T, Brem S. Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas. Geriatr Oncol. 2014 Oct.5(4):389-399. Pubmedid: 25220188.
  • Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Brit J Cancer. 2014 Nov.111(10):1932-1944. Pubmedid: 25290091. Pmcid: PMC4229637.
  • Abernethy A, Abrahams E, Barker A, Buetow K, Burkholder R, Dalton WS, Foti M, Frueh F, Gaynor RB, Kean M, Khan Z, Lessor T, Lichtenfeld JL, Mendelsohn J, Van't Veer L. Turning the tide against cancer through sustained medical innovation: the pathway to progress. Clin Cancer Res. 2014 Mar.20(5):1081-1086. Pubmedid: 24523437.
  • Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan.89(1):62-67. Pubmedid: 24030918. Pmcid: PMC4522918.
  • Shaikh AR, Butte AJ, Schully SD, Dalton WS, Khoury MJ, Hesse BW. Collaborative biomedicine in the age of big data: the case of cancer. J Med Internet Res. 2014 Apr.16(4):e101. Pubmedid: 24711045. Pmcid: PMC4004150.
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep.37(9):1077-1082. Pubmedid: 23809054.
  • Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, Bradner JE, Dalton WS, Sotomayor E, Tao J. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest. 2013 Nov.123(11):4612-4626. Pubmedid: 24216476. Pmcid: PMC3809771.
  • Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013 Dec.27(12):2341-2350. Pubmedid: 23538750. Pmcid: PMC4015113.
  • Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012 Oct.22(4):506-523. Pubmedid: 23079660. Pmcid: PMC3973134.
  • Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012 Nov.18(22):6155-6168. Pubmedid: 22988056. Pmcid: PMC3500436.
  • Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Nov.120(23):4513-4516. Pubmedid: 23018640. Pmcid: PMC3757460.
  • Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012 Nov.18(21 Suppl):S1-100. Pubmedid: 22977188.
  • Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012 Jun.31(24):3002-3008. Pubmedid: 22002311. Pmcid: PMC3982396.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun.157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Wilson DS, Fang B, Dalton WS, Meade CD, Koomen JM. An ET-CURE pilot project supporting undergraduate training in cancer research, emerging technology, and health disparities. J Cancer Educ. 2012 Jun.27(3):418-427. Pubmedid: 22528637. Pmcid: PMC3439555.
  • Wenham RM, Sullivan DM, Hulse M, Jacobsen PB, Dalton WS. The creation of an integrated health-information platform: building the framework to support personalized medicine. Per Med. 2012 Aug.9(6):621-632. Pubmedid: 29768801.
  • Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Mol Cell Proteomics. 2011 Nov.10(11):M110.005520. Pubmedid: 21846842. Pmcid: PMC3226396.
  • Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC, Dalton WS, Sotomayor EM, Wright KL, Tao J. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia. 2011 Jan.25(1):145-152. Pubmedid: 20966935. Pmcid: PMC3083119.
  • Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteom Clin Appl. 2011 Aug.5(7-8):383-396. Pubmedid: 21656910. Pmcid: PMC3530891.
  • Perez LE, Parquet N, Meads M, Anasetti C, Dalton W. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol. 2010 Mar.84(3):212-222. Pubmedid: 19922463.
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb.85(2):197-199. Pubmedid: 20118399. Pmcid: PMC2813833.
  • Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL, Sotomayor EM, Dalton WS, Tao J. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood. 2010 Dec.116(24):5228-5236. Pubmedid: 20841506. Pmcid: PMC3012540.
  • Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, Nefedova Y. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther. 2010 Dec.9(12):3200-3209. Pubmedid: 21159606. Pmcid: PMC3058809.
  • Dalton WS, Sullivan DM, Yeatman TJ, Fenstermacher DA. The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res. 2010 Dec.16(24):5987-5996. Pubmedid: 21169252.
  • Meads MB, Li ZW, Dalton WS. A novel TNF receptor-associated factor 6 binding domain mediates NF-kappa B signaling by the common cytokine receptor beta subunit. J Immunol. 2010 Aug.185(3):1606-1615. Pubmedid: 20622119. Pmcid: PMC3050047.
  • Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010 Apr.115(13):2630-2639. Pubmedid: 20086245. Pmcid: PMC2852365.
  • Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009 Sep.9(9):665-674. Pubmedid: 19693095.
  • Chen RQ, Yang QK, Chen YL, Oliveira VA, Dalton WS, Fearns C, Lee JD. Kinome siRNA screen identifies SMG-1 as a negative regulator of hypoxia-inducible factor-1alpha in hypoxia. J Biol Chem. 2009 Jun.284(25):16752-16758. Pubmedid: 19406746. Pmcid: PMC2719310.
  • Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 2009 Jan.23(1):170-177. Pubmedid: 18843286.
  • Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009 Feb.69(3):1009-1015. Pubmedid: 19155309. Pmcid: PMC2680075.
  • Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec.27(34):5713-5719. Pubmedid: 19786667. Pmcid: PMC2799050.
  • Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009 Dec.69(24):9367-9375. Pubmedid: 19934314. Pmcid: PMC4519834.
  • Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol. 2009 Dec.2(6):649-662. Pubmedid: 21082957.
  • Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol Cancer Ther. 2009 Aug.8(8):2441-2451. Pubmedid: 19671765. Pmcid: PMC2761715.
  • Yeatman TJ, Mule J, Dalton WS, Sullivan D. On the eve of personalized medicine in oncology. Cancer Res. 2008 Sep.68(18):7250-7252. Pubmedid: 18794109. Pmcid: PMC2650840.
  • Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008 Oct.7(10):1780-1794. Pubmedid: 18664563. Pmcid: PMC2559938.
  • Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008 Nov.28(22):6773-6784. Pubmedid: 18794355. Pmcid: PMC2573297.
  • Peramo A, Meads MB, Dalton WS, Matthews WG. Static adhesion of cancer cells to glass surfaces coated with glycosaminoglycans. Colloids Surf B Biointerfaces. 2008 Nov.67(1):140-144. Pubmedid: 18815015.
  • Oliveira V, Romanow WJ, Geisen C, Otterness DM, Mercurio F, Wang HG, Dalton WS, Abraham RT. A protective role for the human SMG-1 kinase against tumor necrosis factor-alpha-induced apoptosis. J Biol Chem. 2008 May.283(19):13174-13184. Pubmedid: 18326048. Pmcid: PMC2442360.
  • Meads M, Hazlehurst L, Dalton W. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008 May.14(9):2519-2526. Pubmedid: 18451212.
  • Nefedova Y, Sullivan D, Bolick S, Dalton W, Gabrilovich D. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008 Feb.111(4):2220-2229. Pubmedid: 18039953.
  • Perez L, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol. 2008 Feb.180(3):1545-1555. Pubmedid: 18209050.
  • Nimmanapalli R, Gerbino E, Dalton W, Gandhi V, Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Brit J Haematol. 2008 Aug.142(4):551-561. Pubmedid: 18503584. Pmcid: PMC4503206.
  • Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007 Sep.110(5):1631-1638. Pubmedid: 17502456. Pmcid: PMC1975846.
  • Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau J, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar S, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine D, Schenkein D, Anderson K. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov.110(10):3557-3560. Pubmedid: 17690257.
  • Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 2007 Jul.21(7):1521-1531. Pubmedid: 17476277.
  • Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Brit J Haematol. 2007 Jan.136(2):269-275. Pubmedid: 17233818.
  • Li Z, Dalton W. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 2006 Nov.20(6):333-342. Pubmedid: 16920238.
  • Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov.108(10):3458-3464. Pubmedid: 16840727. Pmcid: PMC1895441.
  • Dalton W, Anderson K. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res. 2006 Nov.12(22):6603-6610. Pubmedid: 17121878.
  • Dalton W, Friend S. Cancer biomarkers--an invitation to the table. Science. 2006 May.312(5777):1165-1168. Pubmedid: 16728629.
  • Yanamandra N, Colaco N, Parquet N, Buzzeo R, Boulware D, Wright G, Perez LE, Dalton W, Beaupre D. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res. 2006 Jan.12(2):591-599. Pubmedid: 16428505.
  • Hazlehurst L, Argilagos R, Emmons M, Boulware D, Beam C, Sullivan D, Dalton W. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006 Feb.66(4):2338-2345. Pubmedid: 16489039.
  • Friedenberg W, Rue M, Blood E, Dalton W, Shustik C, Larson R, Sonneveld P, Greipp P. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb.106(4):830-838. Pubmedid: 16419071.
  • Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec.108(12):3881-3889. Pubmedid: 16917002. Pmcid: PMC1895461.
  • Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM. Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res. 2005 May.11(9):3335-3341. Pubmedid: 15867232.
  • Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 2005 Jun.105(12):4759-4766. Pubmedid: 15728126. Pmcid: PMC1895008.
  • Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau J, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel J, Blade J, Boccadoro M, Cavenagh J, Dalton W, Boral A, Esseltine D, Porter J, Schenkein D, Anderson K. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun.352(24):2487-2498. Pubmedid: 15958804.
  • Chen Q, Van der Sluis P, Boulware D, Hazlehurst L, Dalton W. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005 Jul.106(2):698-705. Pubmedid: 15802532. Pmcid: PMC1895179.
  • Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld M, Dalton W, Beaupre D. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res. 2005 Aug.11(16):6057-6064. Pubmedid: 16115951.
  • Dalton W. The "total cancer care" concept: linking technology and health care. Cancer Control. 2005 Apr.12(2):140-141. Pubmedid: 15855897.
  • Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, Kortylewski M, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol. 2005 Apr.174(7):3925-3931. Pubmedid: 15778348. Pmcid: PMC2632804.
  • Dalton W. Drug resistance in hematologic malignancies. Clin Adv Hematol Oncol. 2005 Apr.3(4):267-268. Pubmedid: 16166998.
  • Nefedova Y, Cheng P, Alsina M, Dalton W, Gabrilovich D. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004 May.103(9):3503-3510. Pubmedid: 14670925.
  • Engel R, Valkov N, Gump J, Hazlehurst L, Dalton W, Sullivan D. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res. 2004 May.295(2):421-431. Pubmedid: 15093741.
  • Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May.103(9):3271-3277. Pubmedid: 14726402.
  • Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, PatinJ, Knight R, Zeldis J, Dalton W, Anderson K. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004 Jul.79(7):875-882. Pubmedid: 15244383.
  • Dalton WS. The proteasome. Semin Oncol. 2004 Dec.31(6 Suppl 16):3-9. Pubmedid: 15799238.
  • Dalton WS. Proteasome inhibition in hematologic malignancies: clinical update and practical applications. Oncology (Williston Park). 2004 Dec.18(14 Suppl 11):3. Pubmedid: 15688596.
  • Jung L, Holle L, Dalton WS. Discovery, Development, and clinical applications of bortezomib. Oncology (Williston Park). 2004 Dec.18(14 Suppl 11):4-13. Pubmedid: 15688597.
  • Dalton W, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol. 2004 Apr.41(2 Suppl 4):1-5. Pubmedid: 15190509.
  • Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004.10(1):48-54. Pubmedid: 14702634.
  • Hazlehurst L, Landowski T, Dalton W. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 2003 Oct.22(47):7396-7402. Pubmedid: 14576847.
  • Hazlehurst L, Enkemann S, Beam C, Argilagos R, Painter J, Shain K, Saporta S, Boulware L, Moscinski L, Alsina M, Dalton W. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003 Nov.63(22):7900-7906. Pubmedid: 14633719.
  • Dalton W. The tumor microenvironment: focus on myeloma. Cancer Treat Rev. 2003 May.29 Suppl 1:11-19. Pubmedid: 12738239.
  • Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003 Jun.17(6):1175-1182. Pubmedid: 12764386.
  • Sabichi A, Modiano M, Lee J, Peng Y, Xu M, Villar H, Dalton W, Lippman S. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res. 2003 Jul.9(7):2400-2405. Pubmedid: 12855611.
  • Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 2003 Feb.17(2):451-457. Pubmedid: 12592346.
  • Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2003 Apr.51(4):297-305. Pubmedid: 12721757.
  • Landowski T, Olashaw N, Agrawal D, Dalton W. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003 Apr.22(16):2417-2421. Pubmedid: 12717418.
  • Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora L, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton W, Jove R, Yu H. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther. 2002 Sep.1(11):893-899. Pubmedid: 12481410.
  • Shain K, Landowski T, Dalton W. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol. 2002 Mar.168(5):2544-2553. Pubmedid: 11859150.
  • Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec.21(57):8804-8816. Pubmedid: 12483533.
  • Anderson KC, Dalton WS. Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery. Mol Cancer Ther. 2002 Dec.1(14):1361-1365. Pubmedid: 12516971.
  • Dalton W. Drug resistance and drug development in multiple myeloma. Semin Oncol. 2002 Dec.29(6 Suppl 17):21-25. Pubmedid: 12520481.
  • Dalton W. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of re. Clin Cancer Res. 2002 Dec.8(12):3643-3645. Pubmedid: 12473572.
  • Hazelhurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 2001 Sep.98(6):1897-1903. Pubmedid: 11535527.
  • Shain K, Dalton W. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther. 2001 Nov.1(1):69-78. Pubmedid: 12467240.
  • Hazlehurst L, Dalton W. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001 Mar.20(1-2):43-50. Pubmedid: 11831646.
  • Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List A. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol. 2001 Mar.19(6):1589-1599. Pubmedid: 11250987.
  • Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res. 2001 Dec.7(12):4262-4271. Pubmedid: 11751528.
  • Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 2001 Aug.15(8):1232-1239. Pubmedid: 11480565.
  • Grad J, Bahlis N, Reis I, Oshiro M, Dalton W, Boise L. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood. 2001 Aug.98(3):805-813. Pubmedid: 11468182.
  • Niu G, Shain K, Huang M, Ravi R, Bedi A, Dalton W, Jove R, Yu H. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 2001 Apr.61(8):3276-3280. Pubmedid: 11309279.
  • Dalton W, Bergsagel P, Kuehl W, Anderson K, Harousseau J. Multiple myeloma. Hematology Am Soc Hematol Educ Program. 2001.157-177. Pubmedid: 11722983.
  • Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000 Sep.19(38):4319-4327. Pubmedid: 10980607.
  • Fishman M, Dalton W. Considerations in the management of myeloma. Oncology (Williston Park). 2000 Nov.14(11A):72-81. Pubmedid: 11195422.
  • Shain K, Landowski T, Dalton W. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol. 2000 Nov.12(6):557-563. Pubmedid: 11085455.
  • Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia. 2000 May.14(5):830-840. Pubmedid: 10803514.
  • Scheffer G, Maliepaard M, Pijnenborg A, van Gastelen M, de Jong M, Schroeijers A, van der Kolk D, Allen J, Ross D, van der Valk P, Dalton W, Schellens J, Scheper R. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 2000 May.60(10):2589-2593. Pubmedid: 10825126.
  • Shtil A, Turner J, Dalton W, Yu H. Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. Leuk Lymphoma. 2000 Jun.38(1-2):59-70. Pubmedid: 10811448.
  • Damiano J, Dalton W. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000 Jun.38(1-2):71-81. Pubmedid: 10811449.
  • Diaz J, Pow-Sang J, Mora L, Seigne J, Cantor A, Dalton W. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol. 2000 Jul.5(4):149-154. Pubmedid: 10869956.
  • Anderson K, Kyle R, Dalton W, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology Am Soc Hematol Educ Program. 2000 Dec.147-165. Pubmedid: 11701540.
  • Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000 Aug.60(15):4161-4166. Pubmedid: 10945624.
  • Bowman T, Yu H, Sebti S, Dalton W, Jove R. Signal Transducers and Activators of Transcription: Novel Targets for Anticancer Therapeutics. Cancer Control. 1999 Oct.6(5):427-435. Pubmedid: 10758575.
  • Dalton W, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol. 1999 Oct.26(5 Suppl 13):23-27. Pubmedid: 10528891.
  • Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, Yu H. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999 Oct.59(20):5059-5063. Pubmedid: 10537273.
  • Dalton W, Scheper R. Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst. 1999 Oct.91(19):1604-1605. Pubmedid: 10511581.
  • Dalton W. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Updat. 1999 Oct.2(5):285-288. Pubmedid: 11504502.
  • Dalton WS. Pharmacologic Treatment of Cancer: New Developments. Cancer Control. 1999 Oct.6(5):421-422. Pubmedid: 10758574.
  • Catlett-Falcone R, Dalton W, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol. 1999 Nov.11(6):490-496. Pubmedid: 10550013.
  • Martinez R, Raghunand N, Lynch R, Bellamy W, Martinez G, Rojas B, Dalton W, Gillies R. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 1999 May.57(9):1037-1046. Pubmedid: 10796074.
  • Damiano J, Cress A, Hazlehurst L, Shtil A, Dalton W. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999 Mar.93(5):1658-1667. Pubmedid: 10029595. Pmcid: PMC5550098.
  • Shtil A, Turner J, Durfee J, Dalton W, Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood. 1999 Mar.93(6):1831-1837. Pubmedid: 10068654.
  • Hazlehurst L, Foley N, Gleason-Guzman M, Hacker M, Cress A, Greenberger L, De Jong M, Dalton W. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 1999 Mar.59(5):1021-1028. Pubmedid: 10070958.
  • Ross D, Yang W, Abruzzo L, Dalton W, Schneider E, Lage H, Dietel M, Greenberger L, Cole S, Doyle L. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999 Mar.91(5):429-433. Pubmedid: 10070941.
  • Landowski T, Shain K, Oshiro M, Buyuksal I, Painter J, Dalton W. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood. 1999 Jul.94(1):265-274. Pubmedid: 10381522.
  • Rimsza L, Campbell K, Dalton W, Salmon S, Wilcox G, Grogan T. The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. Leuk Lymphoma. 1999 Jul.34(3-4):315-324. Pubmedid: 10439368.
  • Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999 Jan.10(1):105-115. Pubmedid: 10023775.
  • Einstein A, Lush, III R, Rago R, Ko Y, Bubley G, Hener W, Beer T, Chatta G, Shepard R, Unger P, Merica E, Ette E, Harding M, Dalton W. A phase II study of the safety, pharmacokinetics and efficacy of Incel (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in hormone refractory prostate cancer (HRPC). Clin Cancer Res. 1999.5:3836s-3836s.
  • Sullivan D, Partyka J, Fields K, Goldstein S, Field T, Djulbegovic B, Perkins J, McIssac C, Lush, III R, Dalton W. A Phase I study of intensive-dose melphalan, topotecan and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma. Clin Cancer Res. 1999.5:3734s-3734s.
  • Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H. Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther. 1998 May.9(8):1121-1130. Pubmedid: 9625251.
  • Dalton WS. Overview of the Advances in the Treatment of Multiple Myeloma. Cancer Control. 1998 May.5(3):199-200. Pubmedid: 10761053.
  • Taylor C, Green S, Dalton W, Martino S, Rector D, Ingle J, Robert N, Budd T, Paradelo J, Natale R, Bearden J, Mailliard J, Osborne C. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar.16(3):994-999. Pubmedid: 9508182.
  • Hazlehurst L, Gros P, Dalton W. Chromosome mediated gene transfer of drug resistance to mitoxantrone. Anticancer Res. 1998 Mar.18(2A):1005-1010. Pubmedid: 9615755.
  • Dalton WS. Anemia in Multiple Myeloma and Its Management. Cancer Control. 1998 Mar.5(2 Suppl 1):46-50. Pubmedid: 10762467.
  • Izbicka E, Dalton W, Troyer D, Van Hoff D. Expression of two multidrug resistance genes in human prostatic carcinomas. J Natl Cancer Inst. 1998 Jan.90(2):166-167. Pubmedid: 9450583.
  • Miller T, Chase E, Dorr R, Dalton W, Lam K, Salmon S. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs. 1998 Feb.9(2):135-140. Pubmedid: 9510499.
  • Lamy T, Liu J, Landowski T, Dalton W, Loughran, Jr. T. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood. 1998 Dec.92(12):4771-4777. Pubmedid: 9845544.
  • Kickhoefer V, Rajavel K, Scheffer G, Dalton W, Scheper R, Rome L. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem. 1998 Apr.273(15):8971-8974. Pubmedid: 9535882.
  • Rosen S, Dalton W. Therapeutic modalities (Editorial). Curr Opin Oncol. 1998.10:523-524. Pubmedid: noPMID.
  • Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997 Sep.17(9):5612-5619. Pubmedid: 9271436. Pmcid: PMC232409.
  • Chan H, Haddad G, Zheng L, Bradley G, Dalton W, Ling W. Sensitive immunofluorescence detection of the expression of P-glycoprotein in malignant cells. Cytometry. 1997 Sep.29(1):65-75. Pubmedid: 9298813.
  • Dalton W. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol. 1997 Oct.34(4 Suppl 5):3-8. Pubmedid: 9408955.
  • Dalton W. Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 1997 Oct.11(5):975-986. Pubmedid: 9336726.
  • Landowski T, Guzman M, Dalton W. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood. 1997 Mar.89(6):1854-1861. Pubmedid: 9058704.
  • Dalton W. Detection of multidrug resistance gene expression in multiple myeloma. Leukemia. 1997 Jul.11:1166-1169. Pubmedid: 9205007.
  • Dalton WS. Detection of multidrug resistance gene expression in multiple myeloma. Leukemia. 1997 Jul.11(7):1166-1169. Pubmedid: 9205007.
  • Taylor CW, Dalton WS, Mosley K, Dorr RT, Salmon SE. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Res Treat. 1997 Jan.42(1):7-14. Pubmedid: 9116320.
  • Landowski T, Qu N, Buyuksal I, Painter J, Dalton W. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997 Dec.90(11):4266-4270. Pubmedid: 9373236.
  • Wang H, Jiang Z, Wong YW, Dalton WS, Futscher BW, Chan VT. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem Bioph Res Co. 1997 Aug.237(2):217-224. Pubmedid: 9268689.
  • Cellier M, Shustik C, Dalton W, Rich E, Hu J, Malo D, Schurr E, Gros P. Expression of the human NRAMP 1 gene in professional primary phagocytes: studies in blood cells and in HL-60 promyelocytic leukemia. J Leukoc Biol. 1997.61:96-105. Pubmedid: 9000542.
  • Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R, Goodman S, Wolff S, Hu W, Verfaille C, List A, Dalton W, Ognoskie N, Chetrit A, Antin J, Nemunatis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogenic bone marrow transplantation. J Clin Oncol. 1997.15:433-444. Pubmedid: 9053463.
  • Zhao S, Consoli U, Arceci R, Pfeifer J, Dalton WS, Andreeff M. Semi-automated PCR method for quantitating MDR1 expression. Biotechniques. 1996 Oct.21(4):726-731. Pubmedid: 8891227.
  • Futscher B, Foley N, Gleason-Guzman M, Meltzer P, Sullivan D, Dalton W. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer. 1996 May.66(4):520-525. Pubmedid: 8635868.
  • Abbaszadegan M, Foley N, Gleason-Guzman M, Dalton W. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. Int J Cancer. 1996 May.66(4):506-514. Pubmedid: 8635866.
  • Lehnert M, Degiuli R, Kunke K, Emerson S, Dalton W, Salmon S. Serum can inhibit reversal of multidrug resistance by chemosensitisers. Eur J Cancer. 1996 May.32A(5):862-867. Pubmedid: 9081367.
  • List A, Spier C, Grogan T, Johnson C, Roe D, Greer J, Wolff S, Broxterman H, Scheffer G, Scheper R, Dalton W. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996 Mar.87(6):2464-2469. Pubmedid: 8630412.
  • Salmon S, Dalton W. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. J Rheumatol Suppl. 1996 Mar.44:97-101. Pubmedid: 8833064.
  • Beck W, Grogan T, Willman C, Cordon-Cardo C, Parham D, Kuttesch J, Andreef M, Bates S, Berard C, Boyett J, Brophy N, Broxterman H, Chan H, Dalton W, Dietel M, Fojo A, Gascoyne R, Head D, Houghton P, Srivastava D, Lehnert M, Leith C, Paietta E, Pavelic Z, Rimzsa L, Roninson I, Sikic B, Twentyman P, Warnke R, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996 Jul.56(13):3010-3020. Pubmedid: 8674056.
  • Witherspoon SM, Emerson DL, Kerr BM, Dalton WS, Wissell PS. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res. 1996 Jan.2(1):7-12. Pubmedid: 9816083.
  • Dalen JE, Dalton WS. Does lowering cholesterol cause cancer?. Jama. 1996 Jan.275(1):67-69. Pubmedid: 8531290.
  • Glasser L, Dalton WS, Fiederlein RL, Cook P, Powis G, Vogler WR. Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid. Exp Hematol. 1996 Feb.24(2):253-257. Pubmedid: 8641349.
  • Abbaszadegan M, Cress A, Futscher B, Bellamy W, Dalton W. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res. 1996 Dec.56(23):5435-5442. Pubmedid: 8968098.
  • Cress AE, Dalton WS. Multiple drug resistance and intermediate filaments. Cancer Metastasis Rev. 1996 Dec.15(4):499-506. Pubmedid: 9034606.
  • Anderson J, Heindl L, Bauman P, Ludi C, Dalton W. Cytokeratine expression results in a drug resistant phenotype to six different chemotherapeutic agents. Clin Cancer Res. 1996.2:97-105. Pubmedid: 9816096.
  • Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R, Goodman S, Wolff S, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin J, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allgogenic bone marrow transplantation. J Clin Oncol. 1996.15(2):433-444.
  • Vogler WR, Berdel WE, Geller RB, Brochstein JA, Beveridge RA, Dalton WS, Miller KB, Lazarus HM. A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv Exp Med Biol. 1996.416:389-396. Pubmedid: 9131178.
  • Miller TP, Chase EM, Dalton WS, Grogan TM. The phenomenon of multidrug resistance in non-Hodgkin's lymphoma. Cancer Treat Res. 1996.85:107-117. Pubmedid: 9043778.
  • Klimecki W, Taylor C, Dalton W. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. J Clin Immunol. 1995 May.15(3):152-158. Pubmedid: 7559918.
  • Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer. 1995 Feb.75(3):815-820. Pubmedid: 7828131.
  • Bellamy W, Odeleye A, Huizenga E, Dalton W. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. Clin Cancer Res. 1995 Dec.1(12):1563-1570. Pubmedid: 9815957.
  • Neumunaitis J, Rosenfeld C, Ash R, Freedman M, Deeg J, Appelbaum F, Singer J, Flomenberg N, Dalton W, Elfenbein G, Rifkin R, Rubin A, Agosti J, Hayes F, Holcenberg J, Shadduck R. Phase III, double blind placebo controlled trial of rhGN-CSF following allogeneic bone marrow transplant. Bone Marrow Transplant. 1995.15:949-954. Pubmedid: 7581096.
  • Guan X, Meltzer P, Dalton W, Trent J. Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. Nat Genet. 1995.8(2):155-161. Pubmedid: noPMID.
  • Haddad G, Thorner PS, Bradley G, Dalton WS, Ling V, Chan HS. A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow. Lab Invest. 1994 Oct.71(4):595-603. Pubmedid: 7967514.
  • Dalton WS. Is p-glycoprotein a potential target for reversing clinical drug resistance?. Curr Opin Oncol. 1994 Nov.6(6):595-600. Pubmedid: 7827171.
  • Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994 May.83(9):2451-2458. Pubmedid: 7513198.
  • Bauman PA, Dalton WS, Anderson JM, Cress AE. Expression of cytokeratin confers multiple drug resistance. Proc Natl Acad Sci U S A. 1994 Jun.91(12):5311-5314. Pubmedid: 7515497. Pmcid: PMC43984.
  • Klimecki WT, Futscher BW, Dalton WS. Effects of ethanol and paraformaldehyde on RNA yield and quality. Biotechniques. 1994 Jun.16(6):1021-1023. Pubmedid: 7521184.
  • Futscher BW, Abbaszadegan MR, Domann F, Dalton WS. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol. 1994 Apr.47(9):1601-1606. Pubmedid: 8185674.
  • Baumen P, Dalton W, Anderson J, Cress A. Expression of cytokeratin confers multiple drug resistance. Proc Natl Acad Sci U S A. 1994.91:5311-5314.
  • Futscher B, Abbaszadegan M, Domann F, Dalton W. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol. 1994.49(9):1601-1606.
  • Taetle R, Dos Santos B, Ohsugi Y, Koishihara Y, Yamada Y, Messner H, Dalton W. Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma. J Natl Cancer Inst. 1994.86(6):450-455.
  • Klimecki W, Futscher B, Dalton W. Effects of cell-prevention with ethanol and paraformaldehyde on RNA yield and quality. Biotechniques. 1994.16:1021-1023.
  • Abbaszadegan M, Futscher B, Klimecki W, Last A, Dalton W. Analysis of multidrug resistance-associated protein (MRP) mRNA in norman and malignant hematopoietic cells. Cancer Res. 1994.54:4676-4679.
  • Dalton W. Is p-glycoprotein a potential target for reversing clinical drug resistance?. Curr Opin Oncol. 1994.6:595-600.
  • Haddad G, Thorner P, Bradley G, Dalton W, Ling V, Chan H. A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow. Lab Invest. 1994.71(4):595-603.
  • Klimecki W, Futscher B, Grogan T, Dalton W. P-gycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994.83(9):2451-2458.
  • Chan H, Haddad G, Zheng L, Thorner P, Bradley G, Dalton W, Ling V. A sensitive multilayer immunofluorescent method for flow cytometric detection of P-glycoprotein in myeloma and tumor cells. Cytometry. 1994.71(4):595-603.
  • Klimecki W, Futscher B, Dalton W. Effect of ethanol and paraformaldehyde on RNA yield and quality. Biotechniques. 1994.16:1021-1024.
  • Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem. 1994.31:1-61. Pubmedid: 7879670.
  • Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem. 1993 Sep.213(2):414-421. Pubmedid: 8238918.
  • List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol. 1993 Sep.11(9):1652-1660. Pubmedid: 8102639.
  • Bellamy WT, Odeleye A, Finley P, Huizenga B, Dalton WS, Weinstein RS, Hersh EM, Grogan TM. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. Am J Pathol. 1993 Mar.142(3):691-697. Pubmedid: 8456932. Pmcid: PMC1886807.
  • Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993 Jan.81(2):490-495. Pubmedid: 8093668.
  • Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993 Apr.53(7):1475-1479. Pubmedid: 7680954.
  • Nemunaitis J, Rosenfeld C, Ash R, Flomenberg N, Friedman M, Deeg J, Appelbaum F, Singer J, Dalton W, Elfenbein G, Rifkin R, Rubin A, Agosti J, Hayes F, Shadduck R. Phase III double-blind trial of RHGM-CSF (sargramostin) following allogeneic bone marrow transplant (BMT). Blood. 1993.82:286a-286a.
  • Grogan T, Spier C, Salmon S, Matzner M, Rybski J, Weinstein R, Scheper R, Dalton W. P-glcoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993.81(2):490-495.
  • Bellamy W, Odeleye A, Finley P, Huizenga E, Dalton W, Weinstein R, Hersh E, Grogan T. An in vivo model of human multidrug resitant multiple myeloma in SCID mice. Am J Pathol. 1993.142:691-697.
  • Schpeper R, Broxterman H, Scheffer G, Kaajik P, Dalton W, Heijninger T, Kalken C, Slovak M, Vries F, Valk P, Meijer C, Pinedo H. Overexpression of a Mr 110,000 vesicular protein in non-Ppglycoprotein-mediated multidrug resistance. Cancer Res. 1993.53:1475-1479.
  • Dalton W. Drug resistance modulation in the laboratory and the clinic. Semin Oncol. 1993.201(1):64-69.
  • Thompson F, Emerson J, Dalton W, Yang J, McGee D, Villar H, Knox S, Massey K, Weinstein R, Bhattacharya A, Trent J. Clonal chromosome abnormalities in human breast carcinomas I: 28 cases with primary disease. Genes Chromosom Cancer. 1993.7:185-193.
  • Trent J, Yang J, Emerson J, Dalton W, McGee D, Massey K, Thompson F, Villar H. Clonal chromosome abnormalities in human breast carcinoma II: 34 cases with metastic disease. Genes Chromosom Cancer. 1993.7:194-203.
  • List A, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. PhaseI/II trial of Cyclosporine as a chemotherapy-resitance modifier in acute leukemia. J Clin Oncol. 1993.11(9):1652-1660.
  • Lehnert M, Emerson S, Dalton WS, de Giuli R, Salmon SE. In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. J Natl Cancer Inst Monogr. 1993.(15):63-67. Pubmedid: 7912531.
  • Weinstein RS, Hansen KK, McBeath RB, Dalton WS. Expression of the MDR1 gene (P-glycoprotein) in breast cancer. Recent Results Cancer Res. 1993.127:49-54. Pubmedid: 8099226.
  • Futscher BW, Campbell K, Dalton WS. Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil. Cancer Res. 1992 Sep.52(18):5013-5017. Pubmedid: 1387586.
  • Dalton WS, Salmon SE. Drug resistance in myeloma: mechanisms and approaches to circumvention. Hematol Oncol Clin North Am. 1992 Apr.6(2):383-393. Pubmedid: 1582980.
  • Futscher BW, Pieper RO, Dalton WS, Erickson LC. Gene-specific DNA interstrand cross-links produced by nitrogen mustard in the human tumor cell line Colo320HSR. Cell Growth Differ. 1992 Apr.3(4):217-223. Pubmedid: 1515367.
  • Futscher B, Pleper R, Dalton W, Erickson L. Gene-specific DNA interstrand cross-links produced by nitrogen mustard in the human tumor cell line Colo320HSR. Cell Growth Differ. 1992.3(4):217-223.
  • Bensinber W, Buckner C, Clift R, Petersen F, Bianco J, Singer J, Appelbaum F, Dalton W, Beatty P, Fefer A, Storb R, Thomas E, Hansen J. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol. 1992.10(9):1492-1497.
  • List A, Spier C, Dalton W. P-glcoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1992.34:3-10.
  • Futscher B, Pieper R, Dalton W. Gene-specific DNA interstrand cros-links produced by nitrogen mustard in the human tumor cell line Colo320HSR. Cell Growth Differ. 1992.3(4):2117-223.
  • Futscher B, Campbell K, Dalton W. Collateral sensitivity to nitrosources in multi-drug resistant cells selected with verapamil. Cancer Res. 1992.52:5013-5017.
  • Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Brit J Cancer. 1991 Jun.63(6):923-929. Pubmedid: 1676902. Pmcid: PMC1972545.
  • Scheper RJ, Dalton WS, Grogan TM, Schlosser A, Bellamy WT, Taylor CW, Scuderi P, Spier C. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity. Int J Cancer. 1991 Jun.48(4):562-567. Pubmedid: 1710609.
  • Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 1991 Jul.78(1):44-50. Pubmedid: 1676918.
  • Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst. 1991 Jan.83(2):105-110. Pubmedid: 1988684.
  • Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood. 1991 Jan.77(2):348-354. Pubmedid: 1670760.
  • Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 1991 Jan.9(1):17-24. Pubmedid: 1670642.
  • Dalton WS, Grogan TM. Does P-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it?. J Natl Cancer Inst. 1991 Jan.83(2):80-81. Pubmedid: 1671104.
  • Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 1991 Feb.51(3):995-1002. Pubmedid: 1988143.
  • Dalton WS, Grogan TM, Miller TP. The role of P-glycoprotein in drug-resistant hematologic malignancies. Cancer Treat Res. 1991.57:187-208. Pubmedid: 1686717.
  • Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Ocular toxic effects of fenretinide. J Natl Cancer Inst. 1990 Jun.82(12):1063. Pubmedid: 2140863.
  • Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest New Drugs. 1990 Aug.8(3):317-319. Pubmedid: 2148744.
  • Bellamy WT, Dalton WS, Dorr RT. The clinical relevance of multidrug resistance. Cancer Invest. 1990.8(5):547-562. Pubmedid: 1979932.
  • Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody. Cancer Res. 1989 Sep.49(17):4829-4834. Pubmedid: 2569359.
  • Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood. 1989 Oct.74(5):1723-1727. Pubmedid: 2790197.
  • Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst. 1989 May.81(9):696-701. Pubmedid: 2565403.
  • Bellamy WT, Dalton WS, Meltzer P, Dorr RT. Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells. Biochem Pharmacol. 1989 Mar.38(5):787-793. Pubmedid: 2930579.
  • Peng YM, Dalton WS, Alberts DS, Xu MJ, Lim H, Meyskens FL. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer. 1989 Jan.43(1):22-26. Pubmedid: 2521335.
  • Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood. 1989 Feb.73(3):747-752. Pubmedid: 2563664.
  • Roberts RA, Cress AE, Dalton WS. Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochem Pharmacol. 1989 Dec.38(23):4283-4290. Pubmedid: 2597200.
  • Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 1989 Aug.49(16):4542-4549. Pubmedid: 2568172.
  • Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989 Apr.7(4):415-424. Pubmedid: 2564428.
  • Robert NJ, Dalton WS, Osborne CK, Abeloff M. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Horm Res. 1989.32 Suppl 1:221-222. Pubmedid: 2533155.
  • Bellamy WT, Dorr RT, Dalton WS, Alberts DS. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. Cancer Res. 1988 Nov.48(22):6360-6364. Pubmedid: 3180055.
  • Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts DS. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res. 1988 Nov.48(22):6365-6370. Pubmedid: 3180056.
  • Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 1988 May.48(10):2793-2797. Pubmedid: 2896069.
  • Durie BG, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Brit J Haematol. 1988 Feb.68(2):203-206. Pubmedid: 3348977.
  • Cress AE, Roberts RA, Bowden GT, Dalton WS. Modification of keratin by the chemotherapeutic drug mitoxantrone. Biochem Pharmacol. 1988 Aug.37(15):3043-3046. Pubmedid: 2456070.
  • Dalton WS, Cress AE, Alberts DS, Trent JM. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res. 1988 Apr.48(7):1882-1888. Pubmedid: 2894893.
  • Dorr RT, Liddil JD, Trent JM, Dalton WS. Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. Biochem Pharmacol. 1987 Oct.36(19):3115-3120. Pubmedid: 3117061.
  • Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 1986 Oct.46(10):5125-5130. Pubmedid: 2875788.
  • Garewal HS, Dalton WS. Metoclopramide in vincristine-induced ileus. Cancer Treat Rep. 1985 Nov.69(11):1309-1311. Pubmedid: 3867404.
  • Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs. 1985.3(2):101-107. Pubmedid: 4040505.
  • Johnson JM, Lemberger L, Novotny M, Forney RB, Dalton WS, Maskarinec MP. Pharmacological activity of the basic fraction of marihuana whole smoke condensate alone and in combination with delta-9-tetrahydrocannabinol in mice. Toxicol Appl Pharm. 1984 Mar.72(3):440-448. Pubmedid: 6324414.
  • Dalton WS, Alberts DS. Mitoxantrone: a promising new chemotherapeutic agent. Ariz Med. 1984 Feb.41(2):96-98. Pubmedid: 6703919.
  • O'Neil JD, Dalton WS, Forney RB. The effect of cannabichromene on mean blood pressure, heart rate, and respiration rate responses to tetrahydrocannabinol in the anesthetized rat. Toxicol Appl Pharm. 1979 Jun.49(2):265-270. Pubmedid: 494278.
  • Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther. 1976 Mar.19(3):300-309. Pubmedid: 770048.
  • Dalton WS, Martz R, Rodda BE, Lemberger L, Forney RB. Influence of cannabidiol on secobarbital effects and plasma kinetics. Clin Pharmacol Ther. 1976 Dec.20(6):695-700. Pubmedid: 791563.
  • Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Effects of marihuana combined with secobarbital. Clin Pharmacol Ther. 1975 Sep.18(3):298-304. Pubmedid: 1100299.
  • Landowski T, Moscinski L, Burke R, Buyuksal I, Painter J, Goldstein S, Dalton W. CD95 antigen mutations in hematopoietic malignancies. Leuk Lymphoma. 42(5):835-846. Pubmedid: 11697638.
  • Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 17(6):528-536. Pubmedid: 22157297. Pmcid: PMC3240816.
  • Dorr R, Dalton W. Cancer chemotherapy in the elderly. In: Bressler R, Katz M, eds. Geriatric Pharmacology. New York, NY: McGraw Hill; 1993;535-583.
  • Dalton W. Overcoming the multidrug-resistant phenotype. In: DeVita V, Hellman S, Rosenberg S, et al, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia, PA: J. B. Lippencott; 1993;2655-2666.
  • Salmon S, Grogan T, Miller T, Lehnert M, Dalton W. Clinical detectionof multidrug resistance an reversal with chemosensitizing agents. In: Drug resistance as a biochemical target in cancer chemotherapy. 13 ed. Academic Press; 1992;257-269.
  • Dalton W, Salmon S. Drug resistance in myeloma: mechanisms and approaches to circumvention. In: Barlogie B, ed. Hamatology/Oncology clinics of North America. Philadelphia, PA: WB Saunders Co; 1992;383-393.

Patient Comments
Overall Satisfaction

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments